The increasing knowledge on the role of AXL in regulating several aspects of cancer has justified a growing interest in the development and clinical testing of AXL inhibitors for targeted therapies (reviewed in Brown et al., 2016; Gay et al., 2017; Levin et al., 2016). Here, AXL is linked to cancer.